The University of Chicago Header Logo

Connection

Elaine M. Worcester to Calcium Oxalate

Back to Details
This is a "connection" page, showing publications Elaine M. Worcester has written about Calcium Oxalate.
Elaine M. Worcester
Connection Strength
9.954
Calcium Oxalate
  1. Contrasting Response of Urine Stone Risk to Medical Treatment in Calcium Oxalate versus Calcium Phosphate Stone Formers. Kidney360. 2024 Feb 01; 5(2):228-236.
    View in: PubMed
    Score: 0.870
  2. Metabolomic profiles and pathogenesis of nephrolithiasis. Curr Opin Nephrol Hypertens. 2023 09 01; 32(5):490-495.
    View in: PubMed
    Score: 0.840
  3. Stone Morphology Distinguishes Two Pathways of Idiopathic Calcium Oxalate Stone Pathogenesis. J Endourol. 2022 05; 36(5):694-702.
    View in: PubMed
    Score: 0.772
  4. Sex Differences of Kidney Stone Urine Risk Factors after Roux-en-Y Gastric Bypass. Am J Nephrol. 2021; 52(2):173-176.
    View in: PubMed
    Score: 0.715
  5. Evidence for disordered acid-base handling in calcium stone-forming patients. Am J Physiol Renal Physiol. 2020 02 01; 318(2):F363-F374.
    View in: PubMed
    Score: 0.653
  6. Randall's plaque in stone formers originates in ascending thin limbs. Am J Physiol Renal Physiol. 2018 11 01; 315(5):F1236-F1242.
    View in: PubMed
    Score: 0.596
  7. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I. Am J Physiol Renal Physiol. 2013 Dec 01; 305(11):F1574-84.
    View in: PubMed
    Score: 0.426
  8. Pathophysiology-based treatment of idiopathic calcium kidney stones. Clin J Am Soc Nephrol. 2011 Aug; 6(8):2083-92.
    View in: PubMed
    Score: 0.367
  9. Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones. Anat Rec (Hoboken). 2008 Mar; 291(3):325-34.
    View in: PubMed
    Score: 0.289
  10. Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin Nephrol. 2008 Mar; 28(2):111-9.
    View in: PubMed
    Score: 0.289
  11. Mechanism of formation of human calcium oxalate renal stones on Randall's plaque. Anat Rec (Hoboken). 2007 Oct; 290(10):1315-23.
    View in: PubMed
    Score: 0.281
  12. Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int. 2006 Apr; 69(8):1313-8.
    View in: PubMed
    Score: 0.253
  13. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int. 2005 Jul; 68(1):145-54.
    View in: PubMed
    Score: 0.240
  14. Collagen fibrils and cell nuclei are entrapped within Randall's plaques but not in CaOx matrix overgrowth: A microscopic inquiry into Randall's plaque stone pathogenesis. Anat Rec (Hoboken). 2022 07; 305(7):1701-1711.
    View in: PubMed
    Score: 0.188
  15. Demineralization and sectioning of human kidney stones: A molecular investigation revealing the spatial heterogeneity of the stone matrix. Physiol Rep. 2021 01; 9(1):e14658.
    View in: PubMed
    Score: 0.176
  16. Multimodal imaging reveals a unique autofluorescence signature of Randall's plaque. Urolithiasis. 2021 Apr; 49(2):123-135.
    View in: PubMed
    Score: 0.173
  17. In Vivo Renal Tubule pH in Stone-Forming Human Kidneys. J Endourol. 2020 02; 34(2):203-208.
    View in: PubMed
    Score: 0.165
  18. Inhibitors of stone formation. Semin Nephrol. 1996 Sep; 16(5):474-86.
    View in: PubMed
    Score: 0.130
  19. Formation of hydrated calcium oxalates in the presence of poly-L-aspartic acid. Scanning Microsc. 1996; 10(2):415-23; 423-4.
    View in: PubMed
    Score: 0.124
  20. Nephrocalcinosis in Calcium Stone Formers Who Do Not have Systemic Disease. J Urol. 2015 Nov; 194(5):1308-12.
    View in: PubMed
    Score: 0.119
  21. Osteopontin inhibits nucleation of calcium oxalate crystals. Ann N Y Acad Sci. 1995 Apr 21; 760:375-7.
    View in: PubMed
    Score: 0.119
  22. Urinary calcium oxalate crystal growth inhibitors. J Am Soc Nephrol. 1994 Nov; 5(5 Suppl 1):S46-53.
    View in: PubMed
    Score: 0.115
  23. Contrasting histopathology and crystal deposits in kidneys of idiopathic stone formers who produce hydroxy apatite, brushite, or calcium oxalate stones. Anat Rec (Hoboken). 2014 Apr; 297(4):731-48.
    View in: PubMed
    Score: 0.109
  24. The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin. Calcif Tissue Int. 1993 Oct; 53(4):242-8.
    View in: PubMed
    Score: 0.107
  25. The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res. 1992 Sep; 7(9):1029-36.
    View in: PubMed
    Score: 0.099
  26. Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice. Urol Res. 2010 Dec; 38(6):439-52.
    View in: PubMed
    Score: 0.087
  27. Clinical practice. Calcium kidney stones. N Engl J Med. 2010 Sep 02; 363(10):954-63.
    View in: PubMed
    Score: 0.086
  28. Three pathways for human kidney stone formation. Urol Res. 2010 Jun; 38(3):147-60.
    View in: PubMed
    Score: 0.084
  29. Intra-tubular deposits, urine and stone composition are divergent in patients with ileostomy. Kidney Int. 2009 Nov; 76(10):1081-8.
    View in: PubMed
    Score: 0.080
  30. A test of the hypothesis that the collecting duct calcium-sensing receptor limits rise of urine calcium molarity in hypercalciuric calcium kidney stone formers. Am J Physiol Renal Physiol. 2009 Oct; 297(4):F1017-23.
    View in: PubMed
    Score: 0.080
  31. In idiopathic calcium oxalate stone-formers, unattached stones show evidence of having originated as attached stones on Randall's plaque. BJU Int. 2010 Jan; 105(2):242-5.
    View in: PubMed
    Score: 0.079
  32. Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am J Physiol. 1988 Dec; 255(6 Pt 2):F1197-205.
    View in: PubMed
    Score: 0.076
  33. A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall's plaque. BJU Int. 2009 Apr; 103(7):966-71.
    View in: PubMed
    Score: 0.076
  34. Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism. BJU Int. 2009 Mar; 103(5):670-8.
    View in: PubMed
    Score: 0.075
  35. Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Nephrol Dial Transplant. 2009 Jan; 24(1):130-6.
    View in: PubMed
    Score: 0.074
  36. Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int. 2007 Dec; 72(12):1503-11.
    View in: PubMed
    Score: 0.070
  37. Glycoprotein calcium oxalate crystal growth inhibitor in urine. Miner Electrolyte Metab. 1987; 13(4):267-72.
    View in: PubMed
    Score: 0.067
  38. Pathophysiological correlates of two unique renal tubule lesions in rats with intestinal resection. Am J Physiol Renal Physiol. 2006 Nov; 291(5):F1061-9.
    View in: PubMed
    Score: 0.066
  39. Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure. J Clin Invest. 1986 Jun; 77(6):1888-96.
    View in: PubMed
    Score: 0.064
  40. Endoscopic evidence of calculus attachment to Randall's plaque. J Urol. 2006 May; 175(5):1720-4; discussion 1724.
    View in: PubMed
    Score: 0.064
  41. Evidence against a contribution of conventional urine risk factors to de novo ESRD renal stones. Nephrol Dial Transplant. 2006 Mar; 21(3):701-6.
    View in: PubMed
    Score: 0.062
  42. Kidney stone disease. J Clin Invest. 2005 Oct; 115(10):2598-608.
    View in: PubMed
    Score: 0.061
  43. Insights on the pathology of kidney stone formation. Urol Res. 2005 Nov; 33(5):383-9.
    View in: PubMed
    Score: 0.060
  44. A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease. Nat Commun. 2023 07 19; 14(1):4140.
    View in: PubMed
    Score: 0.053
  45. End Point Considerations for Clinical Trials in Enteric Hyperoxaluria. Clin J Am Soc Nephrol. 2023 12 01; 18(12):1637-1644.
    View in: PubMed
    Score: 0.052
  46. Stones from bowel disease. Endocrinol Metab Clin North Am. 2002 Dec; 31(4):979-99.
    View in: PubMed
    Score: 0.050
  47. Clinical Effectiveness of Calcium Oxalate Stone Treatments. Am J Nephrol. 2022; 53(10):761-766.
    View in: PubMed
    Score: 0.050
  48. What treatments reduce kidney stone risk in patients with bowel disease? Urolithiasis. 2022 Oct; 50(5):557-565.
    View in: PubMed
    Score: 0.049
  49. Role of anionic proteins in kidney stone formation: interaction between model anionic polypeptides and calcium oxalate crystals. J Urol. 2000 Apr; 163(4):1343-8.
    View in: PubMed
    Score: 0.042
  50. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int. 1998 Apr; 53(4):952-7.
    View in: PubMed
    Score: 0.036
  51. Osteopontin production by cultured kidney cells. Ann N Y Acad Sci. 1995 Apr 21; 760:266-78.
    View in: PubMed
    Score: 0.030
  52. Biopsy proven medullary sponge kidney: clinical findings, histopathology, and role of osteogenesis in stone and plaque formation. Anat Rec (Hoboken). 2015 May; 298(5):865-77.
    View in: PubMed
    Score: 0.029
  53. Renal histopathology and crystal deposits in patients with small bowel resection and calcium oxalate stone disease. Kidney Int. 2010 Aug; 78(3):310-7.
    View in: PubMed
    Score: 0.021
  54. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int. 2003 Jan; 63(1):255-65.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.